Post-earnings recap
Reported
Thu, Nov 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss per share of $0.21, but the stock saw a slight increase of 0.36% following the earnings release. The lack of revenue data and management commentary leaves investors without clear insights into the company's performance or future direction. The stock's positive reaction may indicate some investor optimism despite the loss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.